csDMARDs in current development, phase, status and mechanism of action
| Molecule | Mechanism of action | Pharmaceutical company/academy | Indications (axSpA/PsA) | Current development phase | Current development stage | Clinical trial no |
| Iguratimod* | Cox2 inhibitor TNF inhibitor | Qilu Hospital of Shandong University | axSpA | III | Recruiting | ChiCTR2000029112 |
*Marketed in China.
axSpA, axial spondyloarthritis; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; PsA, psoriatic arthritis.